The earnings call presented a generally positive outlook, focusing on strengthened financial positions, operational milestones, and upcoming advancements with Veris Health. However, some challenges remain, such as pending Medicare coverage and financial adjustments due to deconsolidation. Overall, the positive aspects outweighed the challenges.

Company Guidance -

Q3 2025

During the PAVmed's First Quarter 2025 Business Update Conference Call, key guidance metrics were highlighted, focusing on the company's strategic positioning and financial status. Lucid Diagnostics, PAVmed's publicly traded subsidiary, reported Q1 revenue of $800,000 with a test volume of 3,034, within their target range of 2,500 to 3,000 tests per quarter. Lucid also enhanced its financial position with a netting of $16.1 million from a public offering, boosting its pro forma cash to $40 million, extending its runway into 2026. PAVmed's CEO, Dr. Lishan Aklog, emphasized Lucid's progress toward securing Medicare coverage and expanding sales channels, particularly in concierge medicine and employer markets. Meanwhile, Veris Health, PAVmed's digital health subsidiary, resumed the development of its implantable monitor, with an FDA filing expected in the first half of 2026. Financially, PAVmed reported a non-GAAP loss of $910,000 for Q1, with operating expenses of approximately $5.4 million, and significant balance sheet improvements were noted, including a $25 million liability reduction.

Strengthened Financial Position

PAVmed significantly strengthened its balance sheet with an underwritten public offering netting $16.1 million, bolstering the balance sheet. Lucid had $40 million in pro forma cash at the end of Q1, extending the runway well into 2026.

Operational Milestones and Advancements

Lucid reported revenue of $800,000 in the last quarter with a test volume of 3,034, at the upper end of the target range of 2,500 to 3,000 tests per quarter. The company is also making progress with new sales channels, including concierge medicine and employer market contracts.

Veris Health Developments

Veris Health has secured financing to restart the development of a critical implantable monitor, with a favorable engagement with the FDA. The company expects to file with the FDA in the first half of 2026.

Positive Financial Metrics

PAVmed showed a large GAAP net income of $18.6 million before NCI and preferred dividends, resulting in a GAAP positive primary EPS of $1.28 per share and a positive diluted EPS of $0.34 per share.

PAVmed (PAVM) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PAVM Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 18, 2025	2025 (Q3)	-0.17 / -	6.437	―	―	―
Aug 14, 2025	2025 (Q2)	-0.13 / -0.74	-1.19	37.82% (+0.45)
May 15, 2025	2025 (Q1)	- / 0.34	-2.62	112.98% (+2.96)
Mar 24, 2025	2024 (Q4)	-0.11 / 0.13	-1.98	106.67% (+2.11)
Nov 14, 2024	2024 (Q3)	1.98 / 6.44	-2.069	411.12% (+8.51)
Aug 13, 2024	2024 (Q2)	-1.45 / -1.19	-1.81	34.25% (+0.62)	―
May 14, 2024	2024 (Q1)	-1.67 / -2.62	-2.456	-6.68% (-0.16)	―
Mar 26, 2024	2023 (Q4)	-1.63 / -1.98	-2.974	33.42% (+0.99)
Nov 14, 2023	2023 (Q3)	-1.77 / -2.07	-3.749	44.81% (+1.68)	―
Aug 14, 2023	2023 (Q2)	-2.33 / -1.81	-3.749	51.72% (+1.94)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PAVM Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 14, 2025	$0.46	$0.46	0.00%
May 15, 2025	$0.73	$0.63	-13.70%
Mar 24, 2025	$0.81	$0.80	-1.23%
Nov 14, 2024	$1.02	$1.09	+6.86%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does PAVmed Inc (PAVM) report earnings?

PAVmed Inc (PAVM) is schdueled to report earning on Nov 18, 2025, Before Open (Confirmed).

What is PAVmed Inc (PAVM) earnings time?

PAVmed Inc (PAVM) earnings time is at Nov 18, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is PAVM EPS forecast?

PAVM EPS forecast for the fiscal quarter 2025 (Q3) is -0.17.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing